Retatrutide Tracker App
Track Your Retatrutide Doses with Pep
Pep is a free retatrutide tracker app for iPhone and Android. Log each weekly dose in mg, record the injection site, set reminders, and keep weight, side effects and nutrition in one record. Retatrutide is investigational and not FDA-approved; Pep is a tracking tool, not a source of medication.
⭐ 4.7 on the App Store and Google Play · 3,000+ ratings

WEEKLY DOSE LOG
Log Every Retatrutide Dose in mg
Retatrutide is a once-weekly injection. In the TRIUMPH-1 trial, participants started at 2 mg and stepped up to a maintenance dose of 4, 9 or 12 mg. Pep logs the dose in mg, the date and the injection site for each shot, reminds you when the next one is due, and keeps every step-up on your timeline so you can see exactly when a dose changed.
SIDE EFFECTS
Record How Each Dose Feels
Side effects were common at the top retatrutide dose in TRIUMPH-1. At 12 mg, 42.4% of participants reported nausea, 32.0% diarrhea, 26.1% constipation and 25.3% vomiting. Pep lets you log each symptom with a severity on the day it happens, tied to the dose on your calendar, so you and your prescriber can see whether symptoms follow a step-up and whether they settle.


PROGRESS & NUTRITION
Track the Results, Not Just the Doses
In TRIUMPH-1, average weight loss at 80 weeks was 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg. Your own trend is what matters. Pep tracks weight, measurements and progress photos next to your dose log, and protein, fiber, calorie and water goals show whether the daily routine is holding up. Food logging with the database and barcode scanner is free; AI photo food scanning is part of Pep Pro.
Compatible GLP-1 Medications
Pep supports retatrutide alongside compounded semaglutide, compounded tirzepatide and every branded GLP-1. If you move between medications, your history stays in one place.
Why Track Retatrutide?
Retatrutide is an investigational once-weekly GLP-1/GIP/glucagon triple agonist from Eli Lilly. It is not FDA-approved. Lilly plans to file with the FDA in the first quarter of 2027, which puts the most likely approval window in late 2027 to early 2028, and on August 3, 2026 Lilly opened a narrow expanded access program for a small group of patients. Our retatrutide FDA approval timeline covers the dates, the TRIUMPH-1 results and who qualifies for early access.
Whether you are in a clinical trial, in the expanded access program, or taking compounded retatrutide under a prescriber, a clear record matters more than usual. A study team or prescriber will want to know the exact dose, the date, the injection site and any symptoms that followed. Pep records all of it in one place and keeps each step-up on your timeline.
If your retatrutide comes in a vial, each dose is a conversion between mg, mL and syringe units. Our free mg to units calculator turns a prescribed mg dose into units for your vial’s concentration, and the units to mg calculator works the other way, telling you how many mg are in the units you drew. Log the resulting mg amount in Pep so your record stays accurate if the concentration changes. Pep also tracks compounded semaglutide and tirzepatide, so moving between medications keeps one continuous history.
Retatrutide Tracker Free Download: How to Get Started
Pep costs $0 on the App Store and Google Play, and the core tracking features stay free. Setup takes about two minutes:
- Download Pep free on iOS or Android using the buttons above.
- Add retatrutide with your current dose in mg.
- Pick your shot day and reminder time, then log your starting weight to begin your trend line.
From there, Pep handles the reminders. When your dose steps up, change the amount and the step is recorded on your timeline.
Retatrutide Tracker App FAQ
Is there a free retatrutide tracker app?
Yes. Pep is free to download on iPhone and Android, and dose logging, reminders, injection-site rotation, weight, side effects and food logging are all free, with free cloud backup. An optional Pro subscription ($39.99 per year) adds AI photo food scanning and the medication-level indicator.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational medication from Eli Lilly. Lilly plans to file with the FDA in the first quarter of 2027, and approval is most likely in late 2027 to early 2028. Anything sold online as retatrutide today is not an approved product. See our retatrutide FDA approval timeline.
What retatrutide doses were studied?
In the TRIUMPH-1 trial (2,339 adults over 80 weeks), participants started at 2 mg weekly and were maintained at 4 mg, 9 mg or 12 mg. Average weight loss was 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg. Pep logs whatever mg amount your prescriber or study team sets; it does not recommend a dose.
Can I switch from semaglutide or tirzepatide and keep my history?
Yes. Add retatrutide as a new medication and your earlier semaglutide or tirzepatide doses, weight trend, progress photos and side-effect notes stay in the same app.
Is Pep the same as Pep AI?
No. Pep GLP-1 Tracker is the free-to-download iPhone and Android app from Shred Apps, LLC for logging GLP-1 doses, weight, food and progress, with an optional Pro subscription. It is separate from Pep AI, a peptide-focused app from a different company. If a store listing does not show Shred Apps, LLC as the developer, it is not our app. See the Pep facts page for details.
Retatrutide is an investigational medication and is not FDA-approved. Pep is a tracking tool; it does not sell, source or recommend any medication and is not medical advice. Follow your prescriber’s or study team’s instructions.



